中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 除本法律意见书特别说明外，若相关数据合计数与各分项数值之和不等于 100%系由四舍五入造成。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标准、 道德规范及勤勉尽责精神，对公司提供的相关文件和有关事实进行了核查和验证， 1 现出具法律意见如下： 一． 本次股东大会的召集、召开程序 关于中国医药健康产业股份有限公司 2025 年第四次临时股东大会法律意见书 致：中国医药健康产业股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受中国医药健康产业股 份有限公司（以下简称"中国医药"或"公司"）的委托，指派律师出席了公司 2025 年第四次临时股东大会（以下简称"本次股东大会"）。本所依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）等相关法律法规以及现行有效的《中国医药健康产 业股份有限公司章程》（以下简称"《公司章程》"）的规定，出具本法律意见 书。 ...

中国医药（600056）公告，下属全资子公司天方药业（600253）收到国家药监局核准签发的福多司坦片 《药品注册证书》。该药品主要用于呼吸道疾病的祛痰治疗，由日本三菱制药株式会社研制，于2001年 12月在日本上市。国家药监局于2023年8月受理注册申请，截至公告披露日，累计研发投入约1161万 元。国内已有5家生产企业获得该药品批件，2023年国内总销售额约为1.17亿元，2024年约为1.28亿元。 ...

Core Viewpoint - The Chinese pharmaceutical industry is experiencing positive changes driven by policy optimization and innovation, with a focus on internationalization and high-quality development [2][3]. Group 1: Industry Development - China's pharmaceutical industry has become a global leader in the production of active pharmaceutical ingredients (APIs) and small to medium-sized medical devices, playing an increasingly important role in the global pharmaceutical landscape [1][2]. - The industry is transitioning from exporting intermediates and APIs to a comprehensive export of innovative products, marking a significant shift in the internationalization of Chinese pharmaceuticals [2][3]. Group 2: Policy and Regulatory Environment - Recent reforms in drug and medical device regulation have enhanced the safety and effectiveness of products while stimulating innovation within the industry [4][5]. - The acceleration of drug review and approval processes, along with China's membership in the International Council for Harmonisation (ICH), has created a "fast track" for innovative drugs to enter international markets [2][3]. Group 3: Market Strategies and Internationalization - Companies are encouraged to adopt differentiated and refined market entry strategies by analyzing regional market characteristics, disease profiles, payment capabilities, and competitive landscapes [3][4]. - Successful case studies highlight the importance of collaboration, local production, and building partnerships to penetrate target markets effectively [5]. Group 4: Challenges and Future Directions - Despite the progress, the industry faces various internal and external challenges that require modernization of the regulatory system and governance capabilities to ensure high-quality development [3][5]. - The industry must maintain confidence and focus on enhancing innovation capabilities and quality control to navigate complex international environments and competition [5].

Core Insights - Jiangsu Province has 16 companies listed in the 2024 China Pharmaceutical Industry Top 100, an increase of one from the previous year, maintaining the highest number in the country for two consecutive years [1][2] - The province's biopharmaceutical cluster achieved over 450 billion yuan in revenue and over 73 billion yuan in profit, both ranking first in the nation [1] - Jiangsu's chemical drug sector surpassed 200 billion yuan, while the medical device sector exceeded 100 billion yuan [1] Industry Overview - The top 100 companies reflect the concentrated development of the pharmaceutical industry in Jiangsu, which has established a solid foundation and competitive advantage nationally [2] - The province has cultivated 8 national manufacturing single champion enterprises and 214 national specialized and innovative "little giant" enterprises [1] - Jiangsu's focus on collaborative innovation and support for innovative drug and medical device development is evident through policies that integrate resources from universities, research platforms, and hospitals [1][2] Company Performance - Among the listed companies, 9 are in the top 50, with Heng Rui Medicine and Zhengda Tianqing Pharmaceutical ranking 8th and 9th respectively [2] - Companies such as Innovent Biologics and Hansoh Pharmaceutical have made significant jumps in rankings, moving up 8 and 5 places respectively [2] - Jiangsu has 5 companies in the top 10 for "2024 R&D Intensity Industrial Enterprises," with Innovent Biologics leading the list [2] Future Outlook - The Jiangsu Provincial Industry and Information Technology Department plans to enhance the "1650" industrial system, focusing on platform synergy, mechanism empowerment, and ecological cultivation [2] - The goal is to strengthen inter-departmental collaboration, improve policy support systems, and accelerate the creation of a biopharmaceutical cluster with international competitiveness [2]

Core Insights - Good Doctor Group's project "Interpreting the Scientific Connotation of Traditional Chinese Medicine and Promoting New Drug Research and Development" won the "2025 Excellent Case of Social Responsibility in China's Pharmaceutical Industry" at the 42nd National Pharmaceutical Industry Information Annual Conference, highlighting its commitment to innovation and responsibility in traditional Chinese medicine [1] Group 1: Research and Development - The chairman of Good Doctor Group, Geng Funeng, proposed the "Four Questions of Traditional Chinese Medicine," providing a research framework for the industry [3] - The company has established partnerships with over 20 universities to create a comprehensive innovation system from genomics research to clinical transformation [3] - Good Doctor Group's core product, Kangfuxin Liquid, has been developed over 20 years and is recognized for its efficacy in wound healing, with annual sales exceeding 1 billion yuan [5] Group 2: Intellectual Property and Achievements - Good Doctor Group holds over 2,000 registered trademarks and has received 460 national patents, including 6 original class new drugs with international PCT patents [6] - The company has been awarded multiple national and provincial honors for its research and innovation efforts [6] Group 3: Social Responsibility and Community Engagement - Good Doctor Group is committed to public health, publishing a series of books on the medicinal benefits of the American cockroach and Kangfuxin Liquid to educate the public [6] - The company has developed the Good Doctor Cloud Medical Platform, connecting over 600,000 grassroots medical institutions to enhance healthcare accessibility [6] Group 4: Future Directions - Good Doctor Group aims to continue leveraging the "Four Questions of Traditional Chinese Medicine" to accelerate drug development and international expansion, revitalizing traditional Chinese medicine through modern technology [7]

Group 1 - The 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing-Changping Life Science Forum were held in Beijing, focusing on the future development of the pharmaceutical industry through insights, ecosystem building, and resource integration [1][3] - The list of "Top 100 Enterprises in China's Pharmaceutical Industry by Main Business Revenue for 2024" was released, with Sichuan Good Doctor Panzhihua Pharmaceutical Co., Ltd. making the list for the 14th consecutive year, showcasing its sustained comprehensive strength [1][3] - Good Doctor Pharmaceutical Group Co., Ltd. received the "2025 China Pharmaceutical Industry Growth Potential Enterprise Map" award, reflecting industry recognition of its future development potential [1][3] Group 2 - The annual conference has been a significant event since its inception in 1959, witnessing the growth and technological innovation of China's pharmaceutical industry [3] - The conference aims to promote the integration of cutting-edge technological innovation concepts with resources from top pharmaceutical companies, driving innovation and transformation in the industry [3] - The global biopharmaceutical industry is undergoing profound changes, with advancements in AI, synthetic biology, gene editing, and cell therapy accelerating China's pharmaceutical industry's shift towards innovation and high-end development [3] Group 3 - In 2024, Good Doctor Group will invest over 800 million yuan to establish a digital intelligent factory for the production of biological raw materials and large-scale traditional Chinese medicine, enhancing production efficiency and product quality [4] - The construction of the second phase of the digital intelligent factory not only improves the production capacity and level of traditional Chinese medicine but also serves as a model for digital projects, promoting high-quality development in the pharmaceutical production sector in Xichang and Liangshan [4]

化学原料药名称：盐酸乌拉地尔 受理号：CYHS2360899 登记号：Y20230001028 证券代码：600056 证券简称：中国医药 公告编号：临 2025-053 号 中国医药健康产业股份有限公司 关于子公司获得化学原料药上市申请批准通知书的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的盐酸乌拉地尔（以下简称"该药品"）《化学 原料药上市申请批准通知书》，现将有关情况公告如下： 一、通知书基本信息 （一）该药品主要用于治疗高血压危象（如血压急剧升高），重度和极重度 高血压以及难治性高血压；用于控制围手术期高血压。 （二）截至本公告披露日，该药品项目原料和制剂研发投入约 731 万元人民 币（未经审计）。 （三）药品市场情况介绍 根据国家药监局药品评审中心原辅包登记信息平台显示，截至本公告披露日， 国内盐酸乌拉地尔原料药共有登记号20个，其中1 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-052 号 中国医药健康产业股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的两份克林霉素磷酸酯注射液（以下简称"该药 品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。 现将有关情况公告如下： 一、通知书基本信息 药品名称：克林霉素磷酸酯注射液 受理号：CYHB2450258、CYHB2450259 通知书编号：2025B02988、2025B02987 剂型：注射剂 规格：4ml:0.6g（按 C₁₈H₃₃ClN₂O₅S 计）、2ml:0.3g（按 C₁₈H₃₃ClN₂O₅S 计） 注册分类：化学药品 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审 ...

Financial Performance - Whirlpool expects a net profit of approximately 205 million yuan for the first half of 2025, an increase of about 174 million yuan or approximately 559% year-on-year [2] - Chipmotion Technology anticipates a net profit between 138 million to 169 million yuan for the first half of 2025, representing a year-on-year growth of approximately 144.46% to 199.37% [2] Mergers and Acquisitions - China Shipbuilding's absorption merger with China Shipbuilding Industry Corporation has been approved by the Shanghai Stock Exchange, pending further regulatory approvals [3] - Guotou Zhonglu plans to acquire 100% of China Electronic Engineering Design Institute through a share issuance, which constitutes a major asset restructuring [4] Shareholder Actions - Aotewei's actual controllers plan to transfer 4.99% of the company's shares, totaling 15.75 million shares, due to personal funding needs [5] - Yaguang Technology's chairman has been placed under detention, but the company's operations remain normal [5] Industry Developments - Ningbo Port expects a 9.8% year-on-year increase in container throughput for the first half of 2025 [8] - Three Trees anticipates a net profit growth of 80.94% to 119.04% for the first half of 2025 [8] - Zhuhai Group expects a net profit increase of 50.97% to 75.23% for the first half of 2025 [8] Project Wins - Sanxing Medical's subsidiary has pre-qualified for a 306 million yuan project with Southern Power Grid [8] - Hopu Co., Ltd. has jointly won a 449 million yuan shared energy storage demonstration project [8] - Hongsheng Huayuan's subsidiary has pre-qualified for an 1.127 billion yuan project with Southern Power Grid [8]

证券代码：600056 证券简称：中国医药 公告编号：临 2025-051 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 规格：5ml:25mg（按 C20H29N5O3计）、10ml:50mg（按 C20H29N5O3计） 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 （一）盐酸乌拉地尔由武田制药研发，于 1981 年在德国上市，于 1993 年在 国内获准上市。主要用于治疗高血压危象（如血压急剧升高），重度和极重度高 血压以及难治性高血压；用于控制围手术期高血压。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的两份盐酸乌拉地尔注射液（以下简称"该药品"） 《药品注册证书》，现将有关情况公告如下： 一、注 ...